Case Managers Streamline Transfer Process

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Prescreening patients before transfer from one cancer facility to another gives the receiving hospital an opportunity to prepare needed services for that patient, "thereby maximizing resources and providing quality care more efficiently," Kathy Rogala-Scherer, RN, Department of Case Management, Roswell Park Cancer Institute (RPCI), said at the 31st Annual Congress of the Oncology Nursing Society (abstract 35).

BOSTON—Prescreening patients before transfer from one cancer facility to another gives the receiving hospital an opportunity to prepare needed services for that patient, "thereby maximizing resources and providing quality care more efficiently," Kathy Rogala-Scherer, RN, Department of Case Management, Roswell Park Cancer Institute (RPCI), said at the 31st Annual Congress of the Oncology Nursing Society (abstract 35).

Key information required to streamline the admitting process includes insurance, demographics, history, and special needs status, and pertinent clinical data supporting the cancer diagnosis. Oncology nurse case managers evaluate the information and review it with the accepting oncologist and with the intensivist if a critical care bed is indicated.

"With prescreening, we can better manage the needs of the patients who come to the Institute," Ms. Rogala-Scherer said. "For example, we can adjust if a patient requires a private room because of being MRSA [methicillin-resistant Staphylococcus aureus] positive or if they have physical limitations, such as being morbidly obese and unable to fit into a standard hospital bed." In this initial review of cases in 2005, RPCI accepted 274 transfers; only 10 patients were declined for transfer.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content